Patient Education Sheet Library
Search Results
Isatuximab and VRd
The combination of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) is used for multiple myeloma.
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads
Download (English) – 0.45MBDaratumumab and VRd
The combination of daratumumab and VRd (bortezomib, lenalidomide, and dexamethasone) is used for multiple myeloma.
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads
Rituximab and Hyaluronidase
The combination of rituximab and hyaluronidase is used for certain types of leukemia and lymphoma.
Treatment Given by InjectionDownloads
Bortezomib
Bortezomib is used for multiple myeloma.
Treatment Given by Infusion Treatment Given by InjectionDownloads
Bortezomib and Dexamethasone
The combination of bortezomib and dexamethasone (Vd) is used for multiple myeloma.
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads
Nivolumab and Hyaluronidase
The combination of nivolumab and hyaluronidase is used for many types of cancer.
Treatment Given by InjectionDownloads
Downloads
Downloads
Downloads
Ropeginterferon Alfa-2b
Ropeginterferon alfa-2b is used for polycythemia vera.
Treatment Given by InjectionDownloads
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
